Adimab scientists will present two posters exploring novel TCR-based T cell engagement strategies: "T cell receptor targeting single-domain antibodies as an alternative to CD3-based T cell engagement" and "Generating potent and specific soluble TCR-based T cell engagers via a high-throughput yeast-based platform."